Help
RSS
API
Feed
Maltego
Contact
Domain > www.athyrium.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2013-04-01
184.172.170.196
(
ClassC
)
2014-03-11
64.78.38.244
(
ClassC
)
2018-05-11
64.41.87.38
(
ClassC
)
2024-07-15
147.135.46.98
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyConnection: Keep-AliveKeep-Alive: timeout5, max100content-type: text/htmlcontent-length: 795date: Mon, 15 Jul 2024 21:13:25 GMTlocation: https://www.athyrium.com/ !DOCTYPE html>html styleheight:100%>head>meta nameviewport contentwidthdevice-width, initial-scale1, shrink-to-fitno />title> 301 Moved Permanently/title>style>@media (prefers-color-scheme:dark){body{background-color:#000!important}}/style>/head>body stylecolor: #444; margin:0;font: normal 14px/20px Arial, Helvetica, sans-serif; height:100%; background-color: #fff;>div styleheight:auto; min-height:100%; > div styletext-align: center; width:800px; margin-left: -400px; position:absolute; top: 30%; left:50%;> h1 stylemargin:0; font-size:150px; line-height:150px; font-weight:bold;>301/h1>h2 stylemargin-top:20px;font-size: 30px;>Moved Permanently/h2>p>The document has been permanently moved./p>/div>/div>/body>/html>
Port 443
HTTP/1.1 200 OKConnection: Keep-AliveKeep-Alive: timeout5, max100content-type: text/html; charsetUTF-8transfer-encoding: chunkeddate: Mon, 15 Jul 2024 21:13:25 GMT !DOCTYPE html>html langen>head>script defer idCookiebot srchttps://consent.cookiebot.com/uc.js data-cbidb6baa93b-ea49-4cf1-9687-78dd311f5026 data-blockingmodeauto typetext/javascript>/script>!-- Google tag (gtag.js) Updated January 2023-->script async srchttps://www.googletagmanager.com/gtag/js?idG-K90KG6MXJG>/script>script> window.dataLayer window.dataLayer || ; function gtag(){dataLayer.push(arguments);} gtag(js, new Date()); gtag(config, G-K90KG6MXJG);/script>script typetext/javascript> var _gaq _gaq || ; _gaq.push(_setAccount, UA-40506353-1); _gaq.push(_trackPageview); (function() { var ga document.createElement(script); ga.type text/javascript; ga.async true; ga.src (https: document.location.protocol ? https://ssl : http://www) + .google-analytics.com/ga.js; var s document.getElementsByTagName(script)0; s.parentNode.insertBefore(ga, s); })();/script>script typetext/javascript srcjs/jquery-1.9.1.min.js>/script> script defer typetext/javascript srcjs/pardot.js>/script> script defer typetext/javascript srcjs/jquery.orbit-1.2.3.min.js>/script>meta http-equivContent-Type contenttext/html; charsetutf-8/>meta namerobots contentindex,follow/>meta namemsvalidate.01 content8CE0A5C8005DA0036B89F0C723785118/>meta nameauthor contentAthyrium Capital Management/>meta namedesigner content45th Parallel Design, LLC, Portland, Oregon/>meta namedescription contentAthyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations./>title>Athyrium Capital Management | Structured Investments in the Global Healthcare Sector/title>link relcanonical hrefhttps://www.athyrium.com/>link relstylesheet typetext/css hrefathyrium.css mediascreen/>link relstylesheet hreforbit-1.2.3.css>!--if lte IE 7>link relstylesheet typetext/css hrefathyriumIE.css>!endif-->link relstylesheet typetext/css hrefforprint.css mediaprint/>link relstylesheet mediaonly screen and (-webkit-min-device-pixel-ratio: 2) hrefhighdpi.css/>link relshortcut icon hreffavicon.ico/>link relshortcut icon hrefimages/favicon.png/>!--if lt IE 9>script srchttp://html5shim.googlecode.com/svn/trunk/html5.js>/script>!endif-->meta namegoogle-site-verification contentGDyMbv5xd8sNspKUBsLU8NJPqKjR0h9_xqawMkeuVOY/>!--script srcjs/foutbgone.js typetext/javascript>/script>script typetext/javascript> fbg.hideFOUT(asap, 20);/script>--> script typetext/javascript> WebFontConfig { custom: { families: clio_c_regularregular, clio_c_semiboldsemibold , urls: font-one.css, font-two.css } }; ( function () { var wf document.createElement( script ); wf.src ( https: document.location.protocol ? https : http ) + ://ajax.googleapis.com/ajax/libs/webfont/1/webfont.js; wf.type text/javascript; wf.async true; var s document.getElementsByTagName( script ) 0 ; s.parentNode.insertBefore( wf, s ); } )(); /script>link relstylesheet typetext/css hreffont-clio.css mediascreen/>/head>body idsplash classmodal>div idheader>div classcontainfloat>ul idinvestor-login>li>a href#>Investor Login/a> ul idinvestor-drop-down> li>a hrefhttps://carl.mufg-is.com/Login/Default.aspx?ruhttp%3a%2f%2fcarl.mufg-is.com%2fdefault.aspx target_blank>AOF I Portal/a>/li> li>a hrefhttps://services.sungarddx.com/LogIn/1214656 target_blank>AOF II Portal/a>/li> li>a hrefhttps://services.sungarddx.com/LogIn/1214656 target_blank>AOF III Portal/a>/li> li>a hrefhttps://services.sungarddx.com/LogIn/1214656 target_blank>AOF IV Portal/a>/li> /ul>/li>/ul>/div>div idlogo>a hrefindex.php>img srcimages/athyriumlogo.jpg altAthyrium Capital Management Logo width223 >/a>/div>nav idmenu>ul classtop_menu> li>a hrefindex.php>Home/a>/li> li>a href#>About Us/a> ul> li>a hrefoverview.php>Overview/a>/li> li>a hrefour-funds.php>Our Funds/a>/li> li>a hrefour-history.php>Our History/a>/li> /ul> /li> li>a href#>Approach/a> ul> li>a hrefcriteria.php>Criteria/a>/li> li>a hrefphilosophy.php>Philosophy/a>/li> li>a hrefstructured-capital.php>What is Structured Capital/a>/li> /ul>/li> li>a hrefteam.php>Team/a> !--ul> li>a hrefferrell.php>Jeffrey A Ferrell/a>/li> li>a hrefhermouet.php>Laurent D. Hermouet/a>/li> li>a hreflack.php>Jeremy D. Lack/a>/li> li>a hrefpines.php>Richard T. Pines/a>/li> li>a hrefhyman.php>Andrew C. Hyman/a>/li> li>a hrefhan.php>Bing Han/a>/li> li>a hrefhelfaer.php>Sam Helfaer/a>/li> li>a hrefgates.php>Nick Gates/a>/li> li>a hreflee.php>Derek Lee/a>/li> li>a hrefporat.php>Samuel N. Porat/a>/li> /ul>--> /li> li>a href#>Portfolio/a> ul> li>a hrefathyrium-opportunities-fund-IV.php>AOF IV/a>/li> li>a hrefathyrium-opportunities-fund-III.php>AOF III/a>/li> li>a hrefathyrium-opportunities-fund-II.php>AOF II/a>/li> li>a hrefathyrium-opportunities-fund.php>AOF I/a>/li> li>a hrefprevious-investments.php>Previous Investments/a>/li> /ul> /li> li>a hrefselect-news.php>News/a>/li> li>a hrefcontact-us.php>Contact Us/a>/li>/ul>/nav>/div> !-- END div idheader -->div idsplash_gray_100_A> /div>!-- END div idsplash_gray_100_A -->div idsplash_gray_100_B> div idsplash_gray_hexagons> div idsplash_gray> h1>Structured Investments in the Global Healthcare Sector/h1> div idmain_statement> p>Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations./p> br> p>Athyrium advises funds with over $4.5 billion of committed capital./p> /div> !-- THE ACTUAL ORBIT SLIDER CONTENT --> div idbig_orbit_container> img idtop-news classreplace-2x height246 width50 srcimages/top-news.png altTop News Section> div idfeatured> !-- div classorbit_content style> h1>Orbit does content now./h1> h3>Highlight me...Im text./h3> /div> a href>img srcdemo/dummy-images/overflow.jpg />/a>--> !--THIS IS THE SECTION THAT CONTROLS THE ORDER OF THE SLIDER--> a hrefdocuments/Calliditas-Refinances-Existing-Term-Loan-With-Secured-Facility-12-27-23.pdf target_blank data-caption#htmlCaptionC>img classreplace-2x srcimages/molecule-model.jpg data-caption#htmlCaptionC altMolecule Photograph/>/a> a hrefdocuments/FDA-Approves-First-Therapeutic-Indication-for-Revances-DAXXIFY-2023-08-14.pdf target_blank data-caption#htmlCaptionD>img classreplace-2x srcimages/microscope.jpg data-caption#htmlCaptionD altMicroscope Photograph/>/a> a hrefdocuments/Syneos-Health-and-uMotif-Partner-on-Patient-Centric-eClinical-Platform-06-26-23.pdf target_blank data-caption#htmlCaptionE>img classreplace-2x srcimages/leaves-in-petri-dishes.jpg data-caption#htmlCaptionE altPetri Dish Photograph/>/a> a hrefdocuments/Humana-Longevity-Health-Expand-Access-Special-Needs-Plans-Medicare-05-04-2023.pdf target_blank data-caption#htmlCaptionF>img classreplace-2x srcimages/red-petri-dishes.jpg data-caption#htmlCaptionF altLab Petri Dish Photograph />/a> a hrefdocuments/Revance-Announces-FDA Approval-of-DAXXIFY-for-Injection-09-08-2022.pdf target_blank data-caption#htmlCaptionG>img classreplace-2x srcimages/tweezers-vials.jpg data-caption#htmlCaptionG altLab Vials Photograph />/a> a hrefdocuments/Basilea-Announces-CHF-75-Million-Senior-Secured-Loan-09-07-2022.pdf target_blank data-caption#htmlCaption>img classreplace-2x srcimages/wheat.jpg data-caption#htmlCaption altWheat Photograph />/a> a hrefdocuments/RVL-Pharmaceuticals-Announces-Insider-and-Athyrium-Led-Financing-08-04-2022.pdf target_blank data-caption#htmlCaptionB>img classreplace-2x srcimages/sequencing-gel.jpg data-caption#htmlCaptionB altDNA gel sequence />/a> !--the MORE can be taken off by using this image src images/red-petri-dishes-no-more.jpg--> /div> !-- End div idfeatured --> !-- Captions for Orbit --> span classorbit-caption idhtmlCaption> a hrefdocuments/Basilea-Announces-CHF-75-Million-Senior-Secured-Loan-09-07-2022.pdf target_blank> h2 classcaption-title>September 7, 2022/h2> p>Basilea Announces CHF 75 Million Senior Secured Loan Agreement with Athyrium/p> /a> /span> span classorbit-caption idhtmlCaptionB> a hrefdocuments/RVL-Pharmaceuticals-Announces-Insider-and-Athyrium-Led-Financing-08-04-2022.pdf target_blank> h2 classcaption-title>August 4, 2022/h2> p>RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing/p> /a> /span> span classorbit-caption idhtmlCaptionC> a hrefdocuments/Calliditas-Refinances-Existing-Term-Loan-With-Secured-Facility-12-27-23.pdf target_blank > h2 classcaption-title>December 23, 2023/h2> p>Calliditas Refinances Existing Term Loan with Euro 92 Million Senior Secured Facility with Athyrium Capital/p> /a> /span> span classorbit-caption idhtmlCaptionD> a hrefdocuments/FDA-Approves-First-Therapeutic-Indication-for-Revances-DAXXIFY-2023-08-14.pdf target_blank> h2 classcaption-title>August 14, 2023/h2> p>U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® for the Treatment of Cervical Dystonia/p> /a> /span> span classorbit-caption idhtmlCaptionE> a hrefdocuments/Syneos-Health-and-uMotif-Partner-on-Patient-Centric-eClinical-Platform-06-26-23.pdf target_blank> h2 classcaption-title>June 26, 2023/h2> p>Syneos Health and uMotif Partner to Deliver Patient-centric eClinical Platform/p> /a> /span> span classorbit-caption idhtmlCaptionF> a hrefdocuments/Humana-Longevity-Health-Expand-Access-Special-Needs-Plans-Medicare-05-04-2023.pdf target_blank> h2 classcaption-title>May 4, 2023/h2> p>Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries/p> /a> /span> span classorbit-caption idhtmlCaptionG> a hrefdocuments/Revance-Announces-FDA Approval-of-DAXXIFY-for-Injection-09-08-2022.pdf target_blank> h2 classcaption-title>September 8, 2022/h2> p>Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection/p> /a> /span> /div> !-- END div idbig_orbit_container --> /div> !-- END div idsplash_gray --> /div> !--END div idsplash_gray_hexagons--> /div>!-- END div idsplash_gray_100_B -->div idsplash_gray_100_C> /div>!-- END div idsplash_gray_100_C -->div idbottom_splash> div idbottom_left> a hrefoverview.php> div classmore> p>MORE/p> /div> /a> div classsplash_teasers> h2>About Us/h2> p>Athyrium is a specialized asset management company which advises funds with over $4.5 billion in committed capital. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations..../p> /div> /div> !-- END div idbottom_left --> !--div idbottom_center> a hrefdocuments/Athyrium-Opportunities-Fund-III-Press-Release.pdf target_blank> div classmore> p>MORE/p> /div> /a> div classsplash_teasers> h2>AOF III Final Close/h2>--> !--PREVIOUS TOMBSTONE div idtombstone> img srcimages/athyrium-logo.png width125 height30 altAthyrium Capital Management Logo > h3>Athyrium Opportunities Fund/h3> p>$507,000,000/p> p>Limited Partnership Interests/p> p>March 2013/p> /div--> !-- a hrefdocuments/Athyrium-Opportunities-Fund-III-Press-Release.pdf target_blank> div idtombstone> img srcimages/athyrium-logo.png width125 height30 altAthyrium Capital Management Logo> h3>AOF III/h3> p>$2,025,000,000/p> p>November 2017/p> /div> /a>--> !-- END div idtombstone --> !--/div> /div>--> !-- END div idbottom_center --> div idbottom_right> !-- a hrefathyrium-opportunities-fund.php> taken out and margin adjusted with .newsletter div classmore> p>MORE/p> /div>/a> --> div classsplash_teasers newsletter> h2>Athyrium Newsletter/h2> p>em>Coming soon.../em> /p> br/> p>Sign up for updates and news from Athyrium Capital Management. Your email will not be distributed or used for any third party purposes./p> !--form actionhttp://athyrium.us4.list-manage.com/subscribe/post?u09aa8ce49eacebe1c0cb67553&ide10bd1b479 methodpost idmc-embedded-subscribe-form namemc-embedded-subscribe-form classvalidate target_blank novalidate> input typeemail value nameEMAIL classemail size40 idmce-EMAIL placeholderemail address required> p idsubmit-button> input typesubmit valueSubscribe namesubscribe idmc-embedded-subscribe classbutton> /p> /form--> /div> /div> !-- END div idbottom_right --> /div>!-- END div idbottom_splash --> div idfooter_100_A> /div> !-- END div idfooter_100_A --> footer idfooter_100_B> div idfooter> p>© 2024 Athyrium Capital Management, LP. All rights reserved. span classfloat_right>a hrefdisclaimer.php>Disclaimer/Privacy Policy/a>/span>/p> /div> !-- END div idfooter --> /footer> !-- END footer idfooter_100_B --> div idfooter_100_C> /div> !-- END div idfooter_100_C --> !--script idCookieDeclaration srchttps://consent.cookiebot.com/b6baa93b-ea49-4cf1-9687-78dd311f5026/cd.js typetext/javascript async>/script-->!--if IE>style typetext/css> .timer { display: none !important; } div.caption { background:transparent; filter:progid:DXImageTransform.Microsoft.gradient(startColorstr#99000000,endColorstr#99000000); zoom: 1; }/style>!endif-->!-- Run the plugin -->script defer typetext/javascript> $(window).on(load, function() { $( #featured ).orbit();}); // $( window ).load( function () { // $( #featured ).orbit(); // } );/script>script> function highdpi_init() { if ( jQuery( .replace-2x ).css( font-size ) 1px ) { var els jQuery( img.replace-2x ).get(); for ( var i 0; i els.length; i++ ) { var src els i .src src src.replace( .jpg, 300ppi.jpg ); els i .src src; } } } jQuery( document ).ready( function () { highdpi_init(); }); /script>/body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]